Noninvasive treatment for pain after COVID-19
Effectiveness of Noninvasive Neuromodulation in Post-COVID Musculoskeletal Pain in the Short Term: Randomized Clinical Trial
NA · University of Alcala · NCT06723821
This study is testing a non-invasive treatment to see if it can help people recovering from COVID-19 feel less pain in their muscles and joints.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University of Alcala (other) |
| Locations | 1 site (Alcalá De Henares, Madrid) |
| Trial ID | NCT06723821 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of non-invasive neuromodulation in alleviating musculoskeletal pain experienced by individuals recovering from COVID-19. Participants will be randomly assigned to either an experimental group receiving the neuromodulation treatment or a sham group receiving a placebo treatment. The study will assess pain levels using the DN4 questionnaire before, during, and after the intervention to determine the treatment's efficacy. The approach focuses on modulating the central nervous system to potentially relieve pain and associated symptoms.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 who have tested positive for COVID-19 within the last three months and are experiencing musculoskeletal pain.
Not a fit: Patients with musculoskeletal pain of traumatic origin, chronic pain lasting more than three months, or those with specific medical conditions such as malignancies or vascular alterations may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide significant relief for patients suffering from post-COVID musculoskeletal pain.
How similar studies have performed: While there is limited specific data on the efficacy of neuromodulation for post-COVID pain, similar non-invasive approaches have shown promise in treating chronic pain conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Positive result in PCR or antigen test for detecting COVID-19 in the last 3 months. * Present musculoskeletal pain in the last 3 months. * Age between 18 to 65 years old. * Score equal or superior to 4 in DN4 scale. Exclusion Criteria: * Present musculoskeletal pain of traumatic origin or known cause * Present musculoskeletal pain with more than 3 months of evolution. * Pregnant women * Present of vascular alterations, malignancy, thrombophlebitis or fever.
Where this trial is running
Alcalá De Henares, Madrid
- Centro Investigación Fisioterapia y Dolor — Alcalá De Henares, Madrid, Spain (RECRUITING)
Study contacts
- Study coordinator: Patricia M Merinero, PhD
- Email: patricia.m.merinero@gmail.com
- Phone: 661637862
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COVID-19, Musculoskeletal Pain